compare suppliers & send inquiries for free
Country of origin
Established in: 1989
6 production facilities approved by USFDA, AGES-Austria, PMDA, WHO
R&D Centers with capabilities of ANDAs, DMFs and NDDS
462+ patents filed for drug substances and polymorphs
Established in: 2005
Portfolio of over 2,000 APIs
Precise quality control
End-to-end global regulatory support
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Varenicline 249296-44-4?
- Here you will find a list of producers, manufacturers and traders of Varenicline. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Cas Number:
- DrugBank number:
- Unique Ingredient Identifier:
What makes Varenicline unique? Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors.
A full agonism was displayed on alpha7-receptors. On March 2015, the USA Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
Ask the supplier for a certificate of analysis to find out more about the quality of Varenicline.
Varenicline is a type of Drugs for nicotine addiction
Pharmaceutical APIs (Active Pharmaceutical Ingredients) are crucial components in the development of drugs to combat nicotine addiction. Nicotine addiction is a significant health concern affecting a large population worldwide. To address this issue, pharmaceutical companies focus on developing effective drugs targeting nicotine addiction, utilizing specialized APIs.
These APIs for nicotine addiction drugs play a pivotal role in the formulation of medications that aid in smoking cessation. They act on specific receptors in the brain, modulating the effects of nicotine and reducing cravings. By targeting these receptors, the APIs facilitate the release of neurotransmitters, such as dopamine, which helps to alleviate withdrawal symptoms and reduce the rewarding effects of smoking.
The development of APIs for nicotine addiction drugs requires meticulous research and stringent quality control measures to ensure safety and efficacy. Pharmaceutical companies employ advanced techniques, such as synthetic chemistry and biotechnology, to synthesize these APIs. Rigorous testing and validation are conducted to meet regulatory standards and ensure consistent drug performance.
APIs used in drugs for nicotine addiction are designed to provide a comprehensive approach to smoking cessation. They may be available in various forms, including oral medications, transdermal patches, or inhalers, allowing individuals to choose the most suitable method for their needs.
In conclusion, pharmaceutical APIs for drugs targeting nicotine addiction play a critical role in combating this widespread health issue. By leveraging advanced synthesis techniques and adhering to stringent quality control measures, these APIs form the foundation for effective medications that help individuals overcome nicotine addiction, contributing to improved public health and well-being.
Varenicline (Drugs for nicotine addiction), classified under Anti-addiction agents
Anti-addiction agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment and management of various forms of addiction. These agents target the neurochemical pathways in the brain that are involved in addiction and dependence, offering therapeutic interventions to individuals struggling with substance abuse disorders.
One prominent group of anti-addiction agents includes opioid receptor antagonists, such as naltrexone and naloxone. These APIs bind to opioid receptors in the brain, blocking the euphoric effects of opioids and reducing cravings. By doing so, they help individuals overcome opioid addiction and prevent relapse.
Another essential class of anti-addiction agents are nicotine receptor agonists, like varenicline. These APIs target nicotine receptors in the brain, reducing the pleasurable sensations associated with smoking and alleviating nicotine withdrawal symptoms. This aids in smoking cessation efforts and enhances long-term abstinence rates.
Furthermore, anti-addiction agents may also encompass APIs used in the treatment of alcohol addiction, such as disulfiram and acamprosate. Disulfiram inhibits the breakdown of alcohol in the body, leading to unpleasant reactions when alcohol is consumed, thus discouraging its use. Acamprosate, on the other hand, helps normalize brain activity disrupted by chronic alcohol use, reducing cravings and promoting abstinence.
In conclusion, anti-addiction agents are a critical category of pharmaceutical APIs used to combat addiction and substance abuse disorders. By targeting specific neurochemical pathways, these agents provide valuable support in overcoming addiction, preventing relapse, and improving the overall well-being of individuals affected by substance abuse.
Varenicline manufacturers | traders | suppliers
We have 10 companies offering Varenicline from 3 different countries.
Get in contact with the supplier of your choice:
- Shilpa Medicare Ltd from India
- LGM Pharma from United States
- Enaltec Labs from India
- Actavis Group from Iceland
- Lee Pharma from India
- Apotex Pharmachem from India
- Lupin from India
- Dr. Reddy's from India
- Mylan from India
- Jubilant Generics from India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.